Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Jennifer Segar
Assistant Professor, Medicine - (Clinical Scholar Track)
Medicine
Overview
Research
More
Collaboration
(32)
Denise Roe
Mutual work: 6 Publications
Collaboration Details
Mohab Ibrahim
Mutual work: 1 Publication
Collaboration Details
Linda Garland
Mutual work: 3 Grants﹒5 Proposals
Collaboration Details
Todd Vanderah
Mutual work: 1 Publication
Collaboration Details
Rina S Fox
Mutual work: 1 Proposal
Collaboration Details
Page 1 of 7
Previous page
Next page
Grants
(31)
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent And Combination Therapy In Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Active
·
2024
·
$0 / $1.6M
·
External
Co-Investigator (COI)
pharmacokinetics,
cancer,
drug therapy,
safety,
dose escalation
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anti-Cancer Therapies in Solid Tumors
Active
·
2024
·
$6.5M / $724K
·
External
Principal Investigator (PI)
cancer,
immunotherapy,
monotherapy,
clinical trial,
solid tumors
A Phase 1 Study With ABBV-CLS-484 Alone And In Combination In Subjects With Locally Advanced or Metastatic Tumors
Active
·
2024
·
$6.3M / $635K
·
External
Principal Investigator (PI)
oncology,
clinical trial,
pharmacology
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant Vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for
Active
·
2024
·
$0 / $559.6K
·
External
Co-Investigator (COI)
breast cancer,
adjuvant therapy,
immunotherapy,
clinical trial,
hormone receptor
A Phase 3 Randomized, Open-label Study Of Op-1250 Monotherapy Vs Standard Of Care For The Treatment Of Er+, Her2- Advanced Or Metastatic Breast Cancer Following Endocrine And Cdk 4/6 Inhibitor Therapy
Active
·
2024
·
$3.1M / $512.6K
·
External
Principal Investigator (PI)
monotherapy,
endocrine therapy,
metastatic breast cancer
Page 1 of 7
Previous page
Next page
Publications
(15)
Recent
Oxylipins as Biomarkers for Aromatase Inhibitor-Induced Arthralgia AIA) in Breast Cancer Patients. Metabolites br br Martinez JA, Wertheim BC, Roe DJ, Taljanovic MS, Chow HS, Chew W, Ehsani S, Jiralerspong S, Segar J Chalasani P. 2023 Mar 20;13(3)452. doi: 10.3390/metabo13030452. PMID: 36984892; PMCID: PMC10052117
2023
biomarkers,
aromatase inhibitor,
arthralgia,
breast cancer,
metabolites
“Real-world data on outcomes using taxane, trastuzumab, and pertuzumab THP) in patients with early stage HER2+ breast cancer
2023
breast cancer,
chemotherapy,
treatment outcomes,
her2+
Investigating keratinocyte growth factor hair serum for the prevention of chemotherapy-induced alopecia.
2022
chemotherapy side effects
The Impact of Hormone Receptor Testing on Breast Cancer Treatment in Dar es Salaam, Tanzania
2021
breast cancer,
hormone receptor,
treatment,
impact,
tanzania
Abstract P3-08-27: Imaging predictors for development of chemotherapy induced peripheral neuropathy
2020
imaging,
chemotherapy,
peripheral neuropathy,
predictors,
development
Diffuse tensor imaging of lower extremities: a novel MR imaging technique for chemotherapy-induced peripheral neuropathy
2020
medical imaging,
neuropathy,
chemotherapy,
lower extremities,
research techniques
Charging forward in locally advanced pancreatic cancer
2020
pancreatic cancer,
cancer treatment,
medical advances,
tumor progression,
therapy development
Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma
2020
cancer,
pathology,
genetics,
molecular biology,
medical research
A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
2019
chemotherapy,
metastatic breast cancer
Elderly AML: A Five-Year Retrospective Review on Prognostic Features
2018
elderly aml,
prognostic features,
aml,
review
